TrialCancer research and treatment2024

Lazertinib versus Gefitinib as First-Line Treatment for EGFR-mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean Subset.

Ki Hyeong Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.